NewLimit, a startup that aims to increase the duration of people a healthy life by genetically planning their cells, has collected a 130 million dollar B led by Kleiner Perkins.
The new Nat Friedman investors, Daniel Gross and Khosla Ventures have also invested, as well as the Fund Fundings Funds, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison and others. Fundraising arrives two years after the company has collected a 40 million dollar series.
Founded over four years ago by the Coinbase Coo Brian Armstrong (pictured above), former partner GV Blake Byers and the jacob Kimmel stem cell professor, NewLimit claims to have made significant progress towards development treatments that can restore the youth characteristics to the elderly cells.
Kimmel told Techcrunch that the company discovered three prototype medicines that reprogram liver cells. NewLimit laboratory experiments said, show that this rejuvenation can restore the ability of cells to process fat and alcohol.
The company measures its progress by contrasting how the cells of a younger individual and an elderly person respond to the substances. An old hepatic cell that has crossed the epigenetic reprogramming of NewLimit behaves more like a younger cell, said Kimmel.
Despite the first results, NewLimit is still a few years after the start of human tests.
In the meantime, the company wants to continue developing a new anti-aging medicine using an artificial intelligence model and therefore test the most promising drugs of these drugs generated by the machine in its laboratory. “What the model AI allows us to do is perform all those experiments in the simulation and therefore follow only the most promising subset,” said Kimmel, adding that the data data points are therefore used to redevelop the model Ai in a process known as “Lab in a cycle”.
Techcrunch event
Berkeley, ca.
|
June 5th
Book now
Other noteworthy biotechnological startups that develop drugs that aim to increase the duration of life include retro biosciences, which have collected $ 180 million from the CEO of Openi Sam Altman two years ago and is reporting a series A of $ 1 billion; and Altos Labs, who launched $ 3 billion in 2022 and is supported by Jeff Bezos.
